|
|
 |
|
Viewing report
|
|
|
|
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
Decision Resources, Inc., Aug 2008, Pages: 33
This report features interviews with top executives and industry experts, who offer insight into current alliances and contribute to a broad perspective on the drivers of current licensing practices.
As the biotechnology industry continues to evolve and mature, many biotech companies are gaining more leverage in negotiating alliances. We analyzed recent deals and interviewed industry executives and experts to gain insight into current alliances and licensing practices. Multiple business and technological factors are converging to reshape the complex biotech-pharma industry landscape.
Get the Answers You Need to Shape Your Strategy
- Rising deal values, evolving deal structures, and increasing competition for quality programs suggest that biotech companies are gaining more bargaining power in negotiating alliances. What factors are influencing current licensing strategies and practices? How are changes in the biotech and pharmaceutical industry affecting deal structures? What deal features are most important in retaining value for the biotech company?
- Facing significant challenges, pharmaceutical companies are incorporating more structures that are advantageous to biotech companies into partnerships. What deal structures characterize recent high-value alliances? How do these features affect each company’s strategic interests? Which biotech companies are negotiating creative deal structures with Big Pharma?
- Big Pharma appears to be regaining interest in collaborating with or acquiring companies with platform technologies. Which biotech companies have platform technologies that interest Big Pharma? What factors make a platform technology valuable to Big Pharma? What are the drivers behind Big Pharma’s interest in platform technology companies?
- With the IPO window effectively closed, M&As provide an appealing exit strategy. What factors influence a company’s decision to use M&A as an exit strategy? How does the current M&A frenzy in biotech affect industry alliances? How can biotech companies protect their value in the event of an acquisition?
Scope
- Monetizing intellectual property and technology: Alnylam Pharmaceuticals/Roche, Alnylam Pharmaceuticals/Takeda; high-value, nonexclusive partnerships; RNA interference); nondilutive capital infusion; copromotion and co-commercialization; opt-ins.
- Moving up the strength curve: Targacept/GlaxoSmithKline; Center for Excellence for External Drug Discovery (CEEDD); neuronal nicotinic receptors; risk-share alliance, “Phase II economics.”
- Codevelopment and co-commercialization: Ariad Pharmaceuticals/Merck; deforolimus; 50-50 development and commercialization; copromotion; booking top-line revenue.
- Mergers & acquisitions: Adnexus Therapeutics/Bristol-Myers Squibb; Adnectins; biologics platform; high-value, early-stage deal followed by acquisition; Infinity Pharmaceuticals/MedImmune and AstraZeneca/MedImmune; impact of M&A; change-of-control; noncompete provisions.
- Academic licensing: Sublicensing provisions; sharing milestone payments; intellectual property provisions in collaborations.
Customers who bought this item also bought
Strategic Alliances in World Pharma and Biotech Markets
Drug Delivery Partnering Agreements in Pharma and Biotech
Biotech M&A Strategies: Deal Assessments, Trends and Future Prospects
Biotech 2009-Life Sciences: Navigating the Sea Change
Analysis of Oncology Deals: Trends in Deal Structures and Valuations
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Trends in Pharmaceutical Deal Making: An Analysis of Valuations, Deal Structures and Deal Types
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Option and Evaluation Agreements in Pharma and Biotech
Pharmaceutical Strategic Alliances: Maximizing Returns from Collaborative Development and Commercialization
|
|
|
|
